Suppliers / Nuray Chemicals

Nuray Chemicals

India 331 employees Updated 9 July 2026

Nuray Chemicals is an API manufacturer based in India. It holds 11 active US drug master files and 2 valid CEPs across a filed portfolio of 10 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 25 June 2024 as NAI. Customs aggregates show $12.3M of exports covering 323 molecules to 27 destinations in 2025.

11
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 25 June 2024 NAI US FDA
  • 3 November 2017 NAI US FDA
  • 13 February 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Tiruvallur, India 3006098295
Thiruvallur, India Not on file

What they file, and where

Molecule Regulators Docs
Pitolisant US FDA 3
Alosetron US FDA 2
Tetraferric Tricitrate Decahydrate US FDA 2
Acebutolol EDQM 1
Atovaquone US FDA 1
Benazepril US FDA 1
Carglumic Acid SFDA (Saudi Arabia) 1
Dapsone EDQM 1
Glycerol Phenylbutyrate US FDA 1
Tranylcypromine US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 1 None
MFDS (Korea) None 2
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.8M 11
2025 Not reported $12.3M 27
2024 Not reported $6.2M 32
2023 Not reported $6.7M 29

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Nuray Chemicals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 25 June 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts